Guidance for palivizumab prophylaxis and implications for compliance
- PMID: 34547834
- DOI: 10.1002/ppul.25634
Guidance for palivizumab prophylaxis and implications for compliance
Keywords: AAP; NPA; RSV; palivizumab; prophylaxis.
References
REFERENCES
-
- Goldstein M, Krilov LR, Fergie J, et al. Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016. Am J Perinatol. 2018;35(14):1433-1442.
-
- Goldstein M, Phillips R, DeVincenzo J, et al. National Perinatal Association 2018 respiratory syncytial virus (RSV) prevntion clinical practice guideline: an evidence-based interdisciplinary collaboration. Neonatol Today. 2017;12(10):1-14. http://dx.doi.org/10.51362/neonatology.today/20171210114
-
- Goldstein M, Krilov LR, Fergie J, et al. Unintended consequences following the 2014 American Academy of Pediatrics policy change for palivizumab prophylaxis among infants born at less than 29 weeks' gestation. Am J Perinatol. 2021.38(S 01):e201-e206. http://dx.doi.org/10.1055/s-0040-1709127
-
- Krilov LR, Fergie J, Goldstein M, Brannman L. Impact of the 2014 American Academy of Pediatrics immunoprophylaxis policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations among preterm infants. Am J Perinatol. 2020;37(2):174-183.
-
- Fergie J, Goldstein M, Krilov LR, Wade SW, Kong AM, Brannman L. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017. Hum Vaccines Immunother. 2021;17(5):1536-1545. http://dx.doi.org/10.1080/21645515.2020.1822134
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
